09.01.2024 -
US Merck, known as MSD outside of North America, intends to buy cancer drug developer Harpoon Therapeutics for $23.00 per share in cash for an approximate equity value of...
Advertising Opportunities Print, Digital & Content Solutions
LinkedIn | X (Twitter)